The influence of CLS 2210 on the course of myocardial infarction: A pilot study in man

L. Szlavy, I. Repa, H. J. Hachen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To assess the effect of CLS 2210 (a new formulation of calcium dobesilate) on the evolution of acute myocardial infarction, 100 patients presenting their first infarct were distributed, according to their sequential admissions to the hospital, into CLS 2210-treated group (50 patients) or a comparison group (50 patients not receiving CLS 2210). The two groups were similar in age, sex, predisposing factors, and site of infarction. Intravenous infusion of CLS 2210 was begun within six hours of onset of chest pain and continued for seventy-two hours. Thereafter, it was given, as oral capsules, in a dose of 1,000 mg every eight hours throughout the hospitalization. Before and during the trial, blood samples were drawn for the measurements of serum concentrations of creatine kinase (CK), and twelve-lead electrocardiograms (ECGs) were obtained serially in each patient. All objective data were analyzed on a coded basis without reference to the treatment. In the comparison group, thirty-six to forty-eight hours was required for CK to fall to 50% of the baseline value, whereas in the CLS 2210-treated group it reached 50% of the baseline in eighteen to twenty-four hours. For each infarction site, a statistically significant fall was reached earlier in the CLS 2210 group. CK, the ECG index, and the sum of the ST segments showed earlier and more rapid improvement in the CLS 2210 group than in the comparison group. The consumption of narcotic analgesic agents and nitroglycerin was substantially less in the CLS 2210 group than in the comparison group. Similarly, lidocaine infusion was employed for 1.2 ± 0.03 days in the CLS 2210-treated patients, whereas the comparison group received lidocaine for 5.7 ± 0.23 days because of continuing cardiac arrhythmias. The agent was well tolerated and no untoward side effects were recorded during the trial. The findings so obtained with CLS 2210, in this pilot study, could have important clinical implications in designing protocols for further trials.

Original languageEnglish
Pages (from-to)639-647
Number of pages9
JournalAngiology
Volume42
Issue number8
Publication statusPublished - 1991

Fingerprint

Myocardial Infarction
Creatine Kinase
Lidocaine
Infarction
Calcium Dobesilate
Electrocardiography
CLS 2210
Sex Factors
Narcotics
Nitroglycerin
Clinical Protocols
Chest Pain
Intravenous Infusions
Causality
Capsules
Analgesics
Cardiac Arrhythmias
Hospitalization
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The influence of CLS 2210 on the course of myocardial infarction : A pilot study in man. / Szlavy, L.; Repa, I.; Hachen, H. J.

In: Angiology, Vol. 42, No. 8, 1991, p. 639-647.

Research output: Contribution to journalArticle

Szlavy, L. ; Repa, I. ; Hachen, H. J. / The influence of CLS 2210 on the course of myocardial infarction : A pilot study in man. In: Angiology. 1991 ; Vol. 42, No. 8. pp. 639-647.
@article{477627d20b86443b977566f4fb6c2f38,
title = "The influence of CLS 2210 on the course of myocardial infarction: A pilot study in man",
abstract = "To assess the effect of CLS 2210 (a new formulation of calcium dobesilate) on the evolution of acute myocardial infarction, 100 patients presenting their first infarct were distributed, according to their sequential admissions to the hospital, into CLS 2210-treated group (50 patients) or a comparison group (50 patients not receiving CLS 2210). The two groups were similar in age, sex, predisposing factors, and site of infarction. Intravenous infusion of CLS 2210 was begun within six hours of onset of chest pain and continued for seventy-two hours. Thereafter, it was given, as oral capsules, in a dose of 1,000 mg every eight hours throughout the hospitalization. Before and during the trial, blood samples were drawn for the measurements of serum concentrations of creatine kinase (CK), and twelve-lead electrocardiograms (ECGs) were obtained serially in each patient. All objective data were analyzed on a coded basis without reference to the treatment. In the comparison group, thirty-six to forty-eight hours was required for CK to fall to 50{\%} of the baseline value, whereas in the CLS 2210-treated group it reached 50{\%} of the baseline in eighteen to twenty-four hours. For each infarction site, a statistically significant fall was reached earlier in the CLS 2210 group. CK, the ECG index, and the sum of the ST segments showed earlier and more rapid improvement in the CLS 2210 group than in the comparison group. The consumption of narcotic analgesic agents and nitroglycerin was substantially less in the CLS 2210 group than in the comparison group. Similarly, lidocaine infusion was employed for 1.2 ± 0.03 days in the CLS 2210-treated patients, whereas the comparison group received lidocaine for 5.7 ± 0.23 days because of continuing cardiac arrhythmias. The agent was well tolerated and no untoward side effects were recorded during the trial. The findings so obtained with CLS 2210, in this pilot study, could have important clinical implications in designing protocols for further trials.",
author = "L. Szlavy and I. Repa and Hachen, {H. J.}",
year = "1991",
language = "English",
volume = "42",
pages = "639--647",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - The influence of CLS 2210 on the course of myocardial infarction

T2 - A pilot study in man

AU - Szlavy, L.

AU - Repa, I.

AU - Hachen, H. J.

PY - 1991

Y1 - 1991

N2 - To assess the effect of CLS 2210 (a new formulation of calcium dobesilate) on the evolution of acute myocardial infarction, 100 patients presenting their first infarct were distributed, according to their sequential admissions to the hospital, into CLS 2210-treated group (50 patients) or a comparison group (50 patients not receiving CLS 2210). The two groups were similar in age, sex, predisposing factors, and site of infarction. Intravenous infusion of CLS 2210 was begun within six hours of onset of chest pain and continued for seventy-two hours. Thereafter, it was given, as oral capsules, in a dose of 1,000 mg every eight hours throughout the hospitalization. Before and during the trial, blood samples were drawn for the measurements of serum concentrations of creatine kinase (CK), and twelve-lead electrocardiograms (ECGs) were obtained serially in each patient. All objective data were analyzed on a coded basis without reference to the treatment. In the comparison group, thirty-six to forty-eight hours was required for CK to fall to 50% of the baseline value, whereas in the CLS 2210-treated group it reached 50% of the baseline in eighteen to twenty-four hours. For each infarction site, a statistically significant fall was reached earlier in the CLS 2210 group. CK, the ECG index, and the sum of the ST segments showed earlier and more rapid improvement in the CLS 2210 group than in the comparison group. The consumption of narcotic analgesic agents and nitroglycerin was substantially less in the CLS 2210 group than in the comparison group. Similarly, lidocaine infusion was employed for 1.2 ± 0.03 days in the CLS 2210-treated patients, whereas the comparison group received lidocaine for 5.7 ± 0.23 days because of continuing cardiac arrhythmias. The agent was well tolerated and no untoward side effects were recorded during the trial. The findings so obtained with CLS 2210, in this pilot study, could have important clinical implications in designing protocols for further trials.

AB - To assess the effect of CLS 2210 (a new formulation of calcium dobesilate) on the evolution of acute myocardial infarction, 100 patients presenting their first infarct were distributed, according to their sequential admissions to the hospital, into CLS 2210-treated group (50 patients) or a comparison group (50 patients not receiving CLS 2210). The two groups were similar in age, sex, predisposing factors, and site of infarction. Intravenous infusion of CLS 2210 was begun within six hours of onset of chest pain and continued for seventy-two hours. Thereafter, it was given, as oral capsules, in a dose of 1,000 mg every eight hours throughout the hospitalization. Before and during the trial, blood samples were drawn for the measurements of serum concentrations of creatine kinase (CK), and twelve-lead electrocardiograms (ECGs) were obtained serially in each patient. All objective data were analyzed on a coded basis without reference to the treatment. In the comparison group, thirty-six to forty-eight hours was required for CK to fall to 50% of the baseline value, whereas in the CLS 2210-treated group it reached 50% of the baseline in eighteen to twenty-four hours. For each infarction site, a statistically significant fall was reached earlier in the CLS 2210 group. CK, the ECG index, and the sum of the ST segments showed earlier and more rapid improvement in the CLS 2210 group than in the comparison group. The consumption of narcotic analgesic agents and nitroglycerin was substantially less in the CLS 2210 group than in the comparison group. Similarly, lidocaine infusion was employed for 1.2 ± 0.03 days in the CLS 2210-treated patients, whereas the comparison group received lidocaine for 5.7 ± 0.23 days because of continuing cardiac arrhythmias. The agent was well tolerated and no untoward side effects were recorded during the trial. The findings so obtained with CLS 2210, in this pilot study, could have important clinical implications in designing protocols for further trials.

UR - http://www.scopus.com/inward/record.url?scp=0025773670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025773670&partnerID=8YFLogxK

M3 - Article

C2 - 1892239

AN - SCOPUS:0025773670

VL - 42

SP - 639

EP - 647

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 8

ER -